Results 141 to 150 of about 27,985 (262)

M3 Muscarinic Receptor Antagonists Inhibit Small Cell Lung Carcinoma Growth and Mitogen-Activated Protein Kinase Phosphorylation Induced by Acetylcholine Secretion [PDF]

, 2007
Pingfang Song, Harmanjatinder S. Sekhon, Allison Lu, Juan Arredondo, David Sauer, Courtney Gravett, Gregory P. Mark, Sergei A. Grando, Eliot R. Spindel   +8 more
openalex   +1 more source

Does Adding Electroanalgesic Modalities to a Multimodal Therapeutic Program Improve Clinical Outcomes in Individuals With Chronic Nonspecific Neck Pain? A Randomised Controlled Trial

European Journal of Pain, Volume 29, Issue 9, October 2025.
ABSTRACT Background Chronic nonspecific neck pain (CNSNP) is a prevalent and complex condition. Although many studies have evaluated the effectiveness of transcutaneous electrical nerve stimulation (TENS), interferential current (IFC), therapeutic exercise (TE), and manual therapy (MT) individually, this study aimed to determine whether adding IFC and ...
Gabriela Nascimento de Santana, Aron Charles Barbosa da Silva, Patrícia Gabrielle dos Santos, Carlos Eduardo Girasol, Adriano Rodrigues de Oliveira, Almir Vieira Dibai‐Filho, Cid André Fidelis de Paula Gomes   +6 more
wiley   +1 more source

Nα-nitro L-arginine methylester and other alkyl esters of L-arginine are muscarinic antagonists

, 1992
Dennis J. Cheek, Delrae M. Eckman, Iain L. O. Buxton, Kathleen D. Keef   +3 more
openalex   +1 more source

Sleep-Predominant Lowering of Ambulatory Blood Pressure by Bedtime Inhalation of a Novel Muscarinic M3 Receptor Antagonist: A New “Bronchoantihypertensive” Strategy Targeting the Lung in Hypertension with Chronic Obstructive Pulmonary Disease [PDF]

, 2008
Kazuomi Kario, Hideyuki Uno, Kazuyuki Shimada   +2 more
openalex   +1 more source

G Protein‐Coupled Receptor Signaling: Implications and Therapeutic Development Advances in Cancers

MedComm, Volume 6, Issue 10, October 2025.
G protein‐coupled receptors (GPCRs) are the dynamic protein family in the human genome. GPCR dysregulation aids in the advancement of cancer through increased migration, survival, and proliferation. Novel treatments that target GPCR signaling include orthosteric ligands, biased receptor mutants, PROTACs, and antibody–drug conjugates.
Inamu Rashid Khan, Sana Khurshid, Saud Almawash, Rakesh Kumar, Ammira S. Al‐Shabeeb Akil, Ajaz A. Bhat, Muzafar A. Macha   +6 more
wiley   +1 more source

Synthesis and Biological Evaluation of Phenylacetyl Derivatives Having Low Central Nervous System Permeability as Potent and Selective M2 Muscarinic Receptor Antagonists.

, 1998
Toshihiro WATANABE, Akio KAKEFUDA, Akihiro Tanaka, Kenji TAKIZAWA, Seiko HIRANO, Hiroshi SHIBATA, Yoko Yamagiwa, Isao YANAGISAWA   +7 more
openalex   +2 more sources

inhibitor 2-[(4-methylphenyl)sulfonylcarbamido]-1-(4-nitrobenzyl)pyridinium bromide (2-AP27) is a muscarinic M2 receptor antagonist [PDF]

, 2009
Vytenis Arvydas Skeberdis, Vida Gendvilienė, Danguolė Zablockaitė, Irma Martišienė, Antanas Stankevičius   +4 more
openalex   +1 more source

Acetylcholinesterase: Structure, dynamics, and interactions with organophosphorus compounds

Protein Science, Volume 34, Issue 10, October 2025.
Abstract Acetylcholinesterase (AChE) is an enzyme that hydrolyzes the neurotransmitter acetylcholine (ACh), removing it from the synaptic cleft after the transmission of an electrical signal, making it an essential component of chemical neurotransmission. AChE is a serine hydrolase, containing a catalytic triad of Ser/His/Glu.
Li‐Wei Hung, Karissa Y. Sanbonmatsu, Robert F. Williams, Julian C.‐H. Chen   +3 more
wiley   +1 more source

A Novel Selective Muscarinic Acetylcholine Receptor Subtype 1 Antagonist Reduces Seizures without Impairing Hippocampus-Dependent Learning [PDF]

, 2009
Douglas J. Sheffler, Richard D. Williams, Thomas M. Bridges, Zixiu Xiang, Alexander S. Kane, Nellie Byun, Satyawan Jadhav, Mathew M. Mock, Fang Zheng, L. Michelle Lewis, Carrie K. Jones, Colleen M. Niswender, Charles D. Weaver, Craig W. Lindsley, P. Jeffrey Conn   +14 more
openalex   +1 more source

A Comparison of the Molecular Pharmacological Properties of Current Short, Long, and Ultra‐Long‐Acting β2‐Agonists Used for Asthma and COPD

Pharmacology Research &Perspectives, Volume 13, Issue 5, October 2025.
ABSTRACT β‐agonists have been used in asthma for 120 years. There are two recent changes: ultra‐long‐acting agonists for COPD and new asthma guidelines recommending formoterol/ICS inhalers phasing out short‐acting salbutamol inhalers. Few studies directly compare the molecular pharmacological properties of short (salbutamol, terbutaline, fenoterol ...
Richard G. W. Proudman, Jillian G. Baker
wiley   +1 more source